Carnitine for fatigue in multiple sclerosis (Q24240036)

Europe PubMed Central

title

Carnitine for fatigue in multiple sclerosis (English)

0 references

0 references

1

Aaron M Tejani

0 references

author name string

Michael Wasdell

2

0 references

Rae Spiwak

3

0 references

Greg Rowell

4

0 references

Shabita Nathwani

Cochrane Database of Systematic Reviews

5

0 references

publication date

17 February 2010

0 references

published in

0 references

cites work

Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Quality of life in patients with multiple sclerosis: the impact of fatigue and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Origin of fatigue in multiple sclerosis: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Antimyopathic effects of carnitine and nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Amantadine for fatigue in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Aminopyridines for symptomatic treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Fatigue in multiple sclerosis persists over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

Fatigue in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021

Fatigue in multiple sclerosis: is the picture getting simpler or more complex?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021

Increased urinary losses of carnitine during ifosfamide chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021

Amantadine therapy for fatigue in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021

The cooling-suit: case studies of its influence on fatigue among eight individuals with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021

Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021

Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021

Treatments for fatigue in multiple sclerosis: a rapid and systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007280.PUB2

7 January 2021